publication date: Mar. 27, 2020
UCLA, UT Southwestern join NCCN
UCLA Jonsson Comprehensive Cancer Center and UT Southwestern Simmons Comprehensive Cancer Center are the newest members of the National Comprehensive Cancer Network.
Experts from both centers will now contribute to NCCN Clinical Practice Guidelines in Oncology.
“We look forward to joining our peer institutions and bringing our focus on cutting-edge research and top-quality cancer care to this association of the nation’s top cancer centers,” Michael Teitell, director of UCLA Jonsson Comprehensive Cancer Center, said in as statement.
“We are excited to be able to join forces with the other leading cancer centers who are part of NCCN,” John Sweetenham, associate director of Clinical Affairs, UT Southwestern Simmons Comprehensive Cancer Center, said in a statement. “Working with the other member institutions, we will ensure that the best possible evidence-based cancer care is available to patients throughout the nation and beyond. Our membership will bring the combined expertise of 30 elite cancer centers to the people of North Texas.”
In 2019, more than 1,500 experts from NCCN member institutions helped create and update NCCN Guidelines. Those guidelines provide the latest evidence- and expert consensus-based recommendations applying to 97% of cancers affecting patients in the United States, and also include prevention, screening, and supportive care topics.
S. Michael Rothenberg joins Pfizer Boulder Research Unit
S. Michael Rothenberg has joined Pfizer as the head of Early Clinical Development at the Boulder Research Unit.
Prior to joining Pfizer, he was vice president of Research and Development at Loxo Oncology, where he led the overall clinical development of selpercatinib (LOXO-292, ARRY-192), a selective RET kinase inhibitor for patients with RET gene-altered cancers, and the early clinical development of LOXO-305, a next generation BTK inhibitor for patients with B-cell malignancies.
“We are very excited that Dr. Rothenberg has joined Pfizer as the head of Early Clinical Development for the Boulder research unit,” Nicholas A. Saccomano, chief scientific officer of Pfizer Boulder Research & Development, said in a statement. “Given his vast experience in medical oncology and developing targeted oncology agents, we have every reason to believe that his expertise will help Pfizer and the Boulder team bring breakthrough medicines to people living with cancer.”
While at Loxo, Rothenberg worked closely with the team at Array BioPharma, which became the Pfizer Boulder Research Unit after its acquisition in June 2019, on the preclinical development of selpercatinib and the next generation TRK kinase inhibitor LOXO-195. Prior to his work in biotechnology, he was a medical oncologist and cancer researcher at the Massachusetts General Hospital Cancer Center.
Kathleen Goss named associate director for administration at University of Chicago Comprehensive Cancer Center
Kathleen Goss was named associate director for administration at the University of Chicago Medicine Comprehensive Cancer Center.
In this role, Goss has broad oversight for administrative and fiscal management of the comprehensive cancer center, including accounting and financial transactions, personnel, IT infrastructure to support clinical trials operations, pre- and post-awards for the Cancer Center Support Grant and multiple interdepartmental grants, cancer center public relations and communications, and philanthropic activities.